Pharmaceuticals & Biopharmaceuticals

New Brunswick, N.J. – November 08, 2026 -- Johnson & Johnson reported that 73% of patients (11 of 15) treated with its pasritamig and JNJ-9401 bispecific antibody combination achieved PSA reductions of at least 50% in a first-in-human Phase 1 study in metastatic castration-resistant prostate cancer (mCRPC). Seven of the 15 patients (47%) reached reductions of at least 90%. The data were presented in a late-breaking oral session at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting (Abstract #1175).

Dual-antigen regimen targets KLK2 and PSMA with complementary T-cell signals

The combination is the first dual-tumor-antigen-targeted bispecific regimen clinically evaluated in prostate cancer. Pasritamig, a first-in-class KLK2xCD3 bispecific, directs T cells toward prostate cancer cells. JNJ-9401, a PSMAxCD28 costimulatory bispecific, adds a second signal meant to strengthen and sustain T-cell activity.

Irvine, Calif. – November 08, 2026 -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), reported a statistically significant 42.4-point mean improvement in FACE-Q Satisfaction With Facial Appearance among 30 adults on GLP-1 medications who received combined neurotoxin and hyaluronic acid (HA) filler treatment. The result comes from HARMONY IN DIVERSITY, which the company describes as the first study of this combination in the GLP-1 population. Data from it and a second Phase 4 study, HALO, were presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting in San Diego, Nov. 5-8.

PLAINSBORO – November 08, 2026 -- Novo Nordisk reported that once-weekly semaglutide 2.4 mg improved liver enzymes and non-invasive markers of disease activity and fibrosis at week 72 in 106 adults with MASH, liver scarring and a BMI below 27 kg/m2, versus placebo.

The post hoc analysis of the phase 3 ESSENCE trial was presented orally at The Liver Meeting 2026 in Denver, Colorado.

Subgroup of 106 patients drawn from 800-patient interim analysis

The subgroup comes from the 800 randomized participants in the 72-week interim analysis of part 1 of ESSENCE. Measures that favored semaglutide included liver injury markers ALT and AST, along with FAST, ELF and PRO-C3. ELF and PRO-C3 are non-invasive fibrosis biomarkers and add fibrosis information alongside biopsy-based endpoints.

Suzhou – November 08, 2026 -- Innovent Biologics (HKEX: 01801) said its PCSK9 antibody SINTBILO (tafolecimab) cut LDL-C by 65.19% at week 12 as monotherapy in the Phase 3 CREDIT-5 study, meeting the primary endpoint. The company plans to file a new-indication application with China's National Medical Products Administration (NMPA) "in the near future".

CREDIT-5 trial shows placebo-adjusted LDL-C drops above 58 points in both dosing regimens

The multi-center, randomized, double-blind, placebo-controlled study enrolled 198 Chinese participants with non-familial hypercholesterolemia and mixed hyperlipidemia. Of these, 131 received tafolecimab and 67 received placebo. Patients were randomized 2:1:2:1 to tafolecimab 150 mg every two weeks (Q2W), placebo Q2W, tafolecimab 450 mg every four weeks (Q4W) or placebo Q4W, after a 4-week run-in during which lipid-lowering products were prohibited.

SHANGHAI – November 08, 2026 -- CureGene Pharmaceutical reported that its investigational P2Y12 antagonist Evategrel (CG-0255) produced comparable pharmacokinetics and platelet inhibition in Chinese and US healthy volunteers, clearing a key hurdle for running global trials in parallel. The data were presented as a poster at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, held November 6-9.

Two clinical pharmacology studies test ethnic and food effects on oral Evategrel

One study compared oral Evategrel pharmacokinetics (PK) and pharmacodynamics (PD) in Chinese and US participants. The second examined how food affects exposure to the oral formulation and its antiplatelet effect. Both used the same design, with one run in the United States and one in China.

NEW BRUNSWICK, N.J. – November 07, 2026 -- Johnson & Johnson reported that 96% of Sjögren's disease patients interviewed after its Phase 2 DAHLIAS study cited mouth dryness as a symptom, making it both the most frequent complaint and the improvement patients prioritized most. The company will present the findings among 23 nipocalimab abstracts at the American College of Rheumatology (ACR) Convergence 2026.

Four core symptoms reported by more than 70% of interviewed patients

Besides mouth dryness (96%), patients most often reported fatigue (92%), eye dryness (90%) and joint pain (73%). Among women, 49% reported vaginal dryness. Patients said they saw improvements across many of these symptoms during the treatment phase.

Sjögren's disease is a chronic, systemic, autoantibody-driven condition affecting approximately four million people worldwide. It is nine times more common in women than in men.

Vancouver – November 07, 2026 -- InMed Pharmaceuticals has completed its merger with privately held Mentari Therapeutics, which closed private financings of approximately $490 million in gross proceeds immediately before the deal. The combined company operates as Mentari Therapeutics, Inc.

Shares begin trading as MTRI on Nasdaq Capital Market on November 9

The combined company's shares are expected to start trading at market open on Monday, November 9, 2026, under the ticker "MTRI" and the new CUSIP number 587157108. The stock previously traded on Nasdaq as INM.

$490 million financing includes $50.0 million in converted notes

The proceeds include the conversion of $50.0 million of previously issued convertible notes, plus accrued interest. Immediately before closing, the company also redomesticated from British Columbia, Canada, to the State of Nevada.

PLAINSBORO, N.J. – November 07, 2026 -- Novo Nordisk reported that adults with metabolic dysfunction-associated steatohepatitis (MASH) who started semaglutide 2.4 mg once weekly lost a statistically significant mean 18.9 lb (8.6 kg; about 8%) from baseline versus patients on resmetirom at six months, according to real-world data presented at AASLD The Liver Meeting 2026 in Denver.

PLATINUM-Truveta compares 2,873 semaglutide patients with 2,285 on resmetirom

The retrospective cohort study drew on de-identified electronic medical records from 30 US health systems in the Truveta database, covering June 2021 through March 2026. Semaglutide 2.4 mg was also associated with significantly greater reductions than resmetirom in AST and some cardiometabolic measures. Researchers assessed ALT, AST, body weight, HbA1c, platelets, triglycerides, HDL and LDL at three and six months.

REHOVOT, Israel – November 05, 2026 -- Evogene Ltd. (Nasdaq: EVGN; TASE: EVGN) will release its third-quarter 2026 financial results on Thursday, November 19, 2026, the computational chemistry company announced.

Management will host a conference call the same day at 9:00 AM Eastern Time (4:00 PM Israel time) to discuss the results. Attendance via Zoom requires advance registration.

Evogene will publish a full conference recording on its website a few days after the call

The company plans to make the entire conference available online shortly after the event, giving investors who miss the live session access to management's commentary.

BOSTON – November 06, 2026 -- Skyhawk Therapeutics has dosed the first U.S. patients in its global pivotal FALCON-HD study of SKY-0515 in Huntington's disease (HD). More than 50,000 doses have been administered to date across more than 30 study sites in 10 countries.

CenExel Colorado site opens U.S. dosing, with Beth Israel Deaconess next

Dosing in the U.S. began at the CenExel Movement Disorder Center in Colorado. Additional U.S. sites, including Beth Israel Deaconess Medical Center, are expected to begin dosing in the coming weeks. Samuel Frank, MD, Director of the HDSA Center of Excellence at Beth Israel Deaconess and a FALCON-HD investigator, expects dosing there before the end of 2026. He described Phase 1/2 results to date as very encouraging.